Beyond Air, INC

Beyond Air announced a private placement raising approximately $10.2 million in gross proceeds, with potential for up to $30.1 million, to fund working capital and the commercial launch of its LungFit PH device.

Beyond Air, Inc. announced a 1-for-20 reverse stock split to regain compliance with Nasdaq listing rules.

Beyond Air reported 107% annual revenue growth to $7.7 million and announced a transition to a December 31st fiscal year-end.

Beyond Air has been granted a conditional extension by the Nasdaq Hearings Panel to regain compliance with the bid price rule by July 31, 2026, with a potential reverse stock split on the horizon.

Beyond Air has requested a hearing before the Nasdaq Hearings Panel to appeal a delisting notice regarding its failure to maintain a $1.00 minimum bid price.

Beyond Air, Inc. reported a 105% year-over-year revenue increase to $2.2 million for its fiscal third quarter, alongside strategic corporate updates and an extended cash runway into 2027.

Beyond Air, Inc. reported significantly reduced net losses and increased revenue for the six months ended September 30, 2025, driven by LungFit PH commercialization and recent capital raises.

Beyond Air, Inc. reported a significant reduction in net loss and increased revenue for the quarter ended June 30, 2025, driven by LungFit PH commercialization and international expansion, despite ongoing liquidity concerns.

Beyond Air's Q3 2025 results show increased revenue but continued net losses as the company focuses on commercialization and strategic adjustments.

Beyond Air's Q2 2025 results show increased revenue but continued losses, alongside securing new financing and restructuring debt.

Beyond Air's Q1 2025 results show increased revenue from LungFit PH sales, but the company continues to operate at a loss while investing in research and development.

Beyond Air, Inc. reported its financial results for the third quarter of fiscal year 2024, highlighting revenue growth and strategic advancements in its nitric oxide technology platform.

Beyond Air reports fiscal year 2026 results, highlighting commercial progress with LungFit PH and ongoing efforts to address going concern risks.

Beyond Air, Inc. reported a net loss of $48.5 million for the fiscal year ended March 31, 2025, with its independent auditors expressing substantial doubt about the company's ability to continue as a going concern despite increased revenue from its LungFit PH system and ongoing capital raising efforts.

Beyond Air, Inc. is advancing its LungFit platform and exploring novel therapies for respiratory, oncological, and neurological conditions, as detailed in its recent annual report.

Robert Scott Goodman, Chief Executive Officer and a Director of Beyond Air, Inc., purchased 104,166 shares of common stock on July 29, 2026 for $5.76 per share.

Daniel J Moorhead, Chief Financial Officer of Beyond Air, Inc., purchased 13,020 shares of common stock on July 29, 2026 for $5.76 per share.

Beyond Air, Inc.'s Chief Financial Officer, Daniel J. Moorhead, received an inducement grant of 70,000 stock options with an exercise price of $0.79 per share.

Beyond Air, Inc. director Yoori Lee's stock options were repriced to an exercise price of $1.95 per share, effective November 4, 2025.

Beyond Air's Chief Operating Officer, Michael A. Gaul, had 53,250 stock options repriced to an exercise price of $1.95 per share.

Beyond Air, Inc. director Robert Carey's stock options were repriced to an exercise price of $1.95 per share, reflecting the company's recent stock performance.

Beyond Air, Inc. is holding a special meeting on June 18, 2026, to vote on a proposed reverse stock split to regain Nasdaq compliance and an adjournment proposal.

Beyond Air, Inc. calls for its 2026 Annual Meeting to elect directors, ratify auditors, and approve an increase in its equity incentive plan shares.

Beyond Air is asking stockholders to approve a reverse stock split, ranging from 1:10 to 1:50, to meet Nasdaq's minimum bid price requirement and avoid delisting.

Beyond Air is convening its 2025 annual meeting to vote on director elections, auditor ratification, equity incentive plan amendments, executive compensation, and an increase in authorized common stock.

Beyond Air, Inc. filed an S-1/A registration statement for the potential resale of up to 1,600,000 common shares by Streeterville Capital, LLC, stemming from a $20 million equity purchase agreement.

Beyond Air, a medical device and biopharmaceutical company, filed an S-1 registration statement for the resale of up to 1.6 million shares by Streeterville Capital, LLC, with the potential to raise up to $20 million for general corporate purposes.

Lin Yi-Chien has filed an amendment to a Schedule 13G, reporting beneficial ownership of 56,000 shares of Beyond Air, Inc. common stock, representing 8.4% of the class.

Lin Yi-Chien has filed a Schedule 13G, reporting beneficial ownership of 1,100,000 shares, representing 8.3% of Beyond Air, Inc.'s common stock.

Alyeska Investment Group, L.P. and associated entities have filed an amendment to their Schedule 13G, reporting a 0% beneficial ownership stake in Beyond Air, Inc.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 763,266 shares, representing 7.25% of Beyond Air, Inc.'s common stock, including shares issuable upon warrant exercise.

Balyasny Asset Management and its affiliates have disclosed a 9.53% beneficial ownership stake in Beyond Air, Inc., including common stock and exercisable warrants.

Balyasny Asset Management and its affiliates reported a 9.27% beneficial ownership stake in Beyond Air, Inc., totaling 763,266 shares.